Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156244 | 0.76 | POLB (0.33) | — | |
| SCHEMBL20222920 | 0.74 | LMNA (0.31) | LMNAMAPT | |
| SCHEMBL9367455 | 0.74 | — | — | |
| SCHEMBL21303013 | 0.68 | LMNA (0.37) | LMNAMAPT | |
| SCHEMBL1833220 | 0.64 | LMNA (0.44) | LMNAMAPT | |
| SCHEMBL20107644 | 0.64 | CDK8 (0.32) | — | |
| SCHEMBL24375220 | 0.62 | RGS4 (0.30) | — | |
| SCHEMBL14365542 | 0.61 | — | — | |
| SCHEMBL24375216 | 0.58 | ADORA3 (0.32) | — | |
| SCHEMBL32659880 | 0.58 | GAA (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-05-12 | — | — | US | disclosed |
| US-9221838-B2 | Inhibitors of AKT activity | ALMAC DISCOVERY LIMITED (IE) | 2015-12-29 | — | — | US | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130116243-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116243-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | LMNA 3443/4885MAPT 1269/4885 |
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | BACE1, ENGASE, GBA3 | LMNA 632/4885MAPT 34/4885 |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | LMNA 2995/4885MAPT 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.